http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 09:28:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++PSYENCE+BIOMEDICAL+LTD.++++++++++++++++Filed+by%3A+Psyence+Labs+Ltd/26596684.html si-local-file:///var/storage/secattach/20260603/26596684.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++PSYENCE+BIOMEDICAL+LTD.++++++++++++++++Filed+by%3A+Psyence+Labs+Ltd/26596684.html Wed, 03 Jun 2026 09:28:00 -0400 O.03270327 O.65258044 PBM PSYGD http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++PSYENCE+BIOMEDICAL+LTD.++++++++++++++++Filed+by%3A+Psyence+Labs+Ltd/26596684.html si-local-file:///var/storage/secattach/20260603/26596684.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++PSYENCE+BIOMEDICAL+LTD.++++++++++++++++Filed+by%3A+Psyence+Labs+Ltd/26596684.html Wed, 03 Jun 2026 09:28:00 -0400 O.03270327 O.65258044 PBM PSYGD http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++PSYENCE+BIOMEDICAL+LTD.++++++++++++++++Filed+by%3A+Psyence+Labs+Ltd/26596684.html si-local-file:///var/storage/secattach/20260603/26596684.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++PSYENCE+BIOMEDICAL+LTD.++++++++++++++++Filed+by%3A+Psyence+Labs+Ltd/26596684.html Wed, 03 Jun 2026 09:28:00 -0400 O.03270327 O.65258044 PBM PSYGD http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++PSYENCE+BIOMEDICAL+LTD.++++++++++++++++Filed+by%3A+Psyence+Labs+Ltd/26596684.html si-local-file:///var/storage/secattach/20260603/26596684.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++PSYENCE+BIOMEDICAL+LTD.++++++++++++++++Filed+by%3A+Psyence+Labs+Ltd/26596684.html Wed, 03 Jun 2026 09:28:00 -0400 O.03270327 O.65258044 PBM PSYGD http://www.streetinsider.com/Corporate+News/Psyence+BioMed+executives+to+visit+US+for+ibogaine+research+meetings/26500645.html <p>Psyence BioMed Ltd. (NASDAQ: PBM) announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in psychedelic medicine research and policy initiatives.</p><p>The company said the visit follows recent U.S. policy developments supporting increased research collaboration and clinical investigation involving psychedelic compounds, including ibogaine. Chief Executive Officer Jody Aufrichtig submitted a formal letter to President Donald J. Trump and U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. regarding the Administration's research initiatives involving psychedelic compounds.</p><p>The purpose of the engagement http://www.streetinsider.com/Corporate+News/Psyence+BioMed+executives+to+visit+US+for+ibogaine+research+meetings/26500645.html Fri, 15 May 2026 09:15:54 -0400 PBM http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+U.S.+Strategic+Engagement+Initiative+Focused+on+GMP+Ibogaine+Research+and+Manufacturing/26500628.html <p align="justify">NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives.</p> <p align="justify">The visit follows recent U.S. policy developments supporting increased research collaboration, regulatory review pathways, and clinical investigation involving psychedelic compounds, http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+U.S.+Strategic+Engagement+Initiative+Focused+on+GMP+Ibogaine+Research+and+Manufacturing/26500628.html Fri, 15 May 2026 09:15:00 -0400 PBM PBM http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+U.S.+Strategic+Engagement+Initiative+Focused+on+GMP+Ibogaine+Research+and+Manufacturing/26500628.html <p align="justify">NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives.</p> <p align="justify">The visit follows recent U.S. policy developments supporting increased research collaboration, regulatory review pathways, and clinical investigation involving psychedelic compounds, http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+U.S.+Strategic+Engagement+Initiative+Focused+on+GMP+Ibogaine+Research+and+Manufacturing/26500628.html Fri, 15 May 2026 09:15:00 -0400 PBM PBM http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+U.S.+Strategic+Engagement+Initiative+Focused+on+GMP+Ibogaine+Research+and+Manufacturing/26500628.html <p align="justify">NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives.</p> <p align="justify">The visit follows recent U.S. policy developments supporting increased research collaboration, regulatory review pathways, and clinical investigation involving psychedelic compounds, http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+U.S.+Strategic+Engagement+Initiative+Focused+on+GMP+Ibogaine+Research+and+Manufacturing/26500628.html Fri, 15 May 2026 09:15:00 -0400 PBM PBM http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+U.S.+Strategic+Engagement+Initiative+Focused+on+GMP+Ibogaine+Research+and+Manufacturing/26500628.html <p align="justify">NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives.</p> <p align="justify">The visit follows recent U.S. policy developments supporting increased research collaboration, regulatory review pathways, and clinical investigation involving psychedelic compounds, http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+U.S.+Strategic+Engagement+Initiative+Focused+on+GMP+Ibogaine+Research+and+Manufacturing/26500628.html Fri, 15 May 2026 09:15:00 -0400 PBM PBM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Apr+23/26360264.html si-local-file:///var/storage/secattach/20260423/26360264.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Apr+23/26360264.html Thu, 23 Apr 2026 18:56:00 -0400 O.65258044 PBM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Apr+23/26360264.html si-local-file:///var/storage/secattach/20260423/26360264.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Apr+23/26360264.html Thu, 23 Apr 2026 18:56:00 -0400 O.65258044 PBM http://www.streetinsider.com/Corporate+News/Psyence+BioMed+begins+dosing+patients+in+phase+IIb+psilocybin+trial/26354361.html <p>Psyence Biomedical Ltd. (NASDAQ: PBM) announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 for the treatment of Adjustment Disorder in cancer patients receiving palliative care.</p><p>NPX-5 contains 25mg of nature-derived psilocybin and is manufactured under Good Manufacturing Practice standards. The compound was developed through Psyence BioMed's investment in PsyLabs as part of its vertically integrated platform.</p><p>The randomized, double-blind, three-arm study is designed to evaluate the safety and efficacy of 25mg psilocybin in patients experiencing Adjustment Disorder related to a cancer diagnosis. The trial is being conducted across five clinical sites in Australia, including http://www.streetinsider.com/Corporate+News/Psyence+BioMed+begins+dosing+patients+in+phase+IIb+psilocybin+trial/26354361.html Thu, 23 Apr 2026 07:01:22 -0400 PBM http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html <p align="justify">NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.</p> <p align="justify">The initiation of dosing represents the first active clinical evaluation of NPX-5 at scale and marks the Company’s transition into systematic human data generation across its Australian clinical network.</p> <p align="justify">NPX-5 is http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html Thu, 23 Apr 2026 07:00:00 -0400 A.06822034 A.17150087 O.20026344 O.49223070 O.65258044 PBM http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html <p align="justify">NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.</p> <p align="justify">The initiation of dosing represents the first active clinical evaluation of NPX-5 at scale and marks the Company’s transition into systematic human data generation across its Australian clinical network.</p> <p align="justify">NPX-5 is http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html Thu, 23 Apr 2026 07:00:00 -0400 A.06822034 A.17150087 O.20026344 O.49223070 O.65258044 PBM http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html <p align="justify">NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.</p> <p align="justify">The initiation of dosing represents the first active clinical evaluation of NPX-5 at scale and marks the Company’s transition into systematic human data generation across its Australian clinical network.</p> <p align="justify">NPX-5 is http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html Thu, 23 Apr 2026 07:00:00 -0400 A.06822034 A.17150087 O.20026344 O.49223070 O.65258044 PBM http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html <p align="justify">NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.</p> <p align="justify">The initiation of dosing represents the first active clinical evaluation of NPX-5 at scale and marks the Company’s transition into systematic human data generation across its Australian clinical network.</p> <p align="justify">NPX-5 is http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html Thu, 23 Apr 2026 07:00:00 -0400 A.06822034 A.17150087 O.20026344 O.49223070 O.65258044 PBM http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html <p align="justify">NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.</p> <p align="justify">The initiation of dosing represents the first active clinical evaluation of NPX-5 at scale and marks the Company’s transition into systematic human data generation across its Australian clinical network.</p> <p align="justify">NPX-5 is http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html Thu, 23 Apr 2026 07:00:00 -0400 A.06822034 A.17150087 O.20026344 O.49223070 O.65258044 PBM http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html <p align="justify">NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.</p> <p align="justify">The initiation of dosing represents the first active clinical evaluation of NPX-5 at scale and marks the Company’s transition into systematic human data generation across its Australian clinical network.</p> <p align="justify">NPX-5 is http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html Thu, 23 Apr 2026 07:00:00 -0400 A.06822034 A.17150087 O.20026344 O.49223070 O.65258044 PBM http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html <p align="justify">NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.</p> <p align="justify">The initiation of dosing represents the first active clinical evaluation of NPX-5 at scale and marks the Company’s transition into systematic human data generation across its Australian clinical network.</p> <p align="justify">NPX-5 is http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html Thu, 23 Apr 2026 07:00:00 -0400 A.06822034 A.17150087 O.20026344 O.49223070 O.65258044 PBM http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html <p align="justify">NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.</p> <p align="justify">The initiation of dosing represents the first active clinical evaluation of NPX-5 at scale and marks the Company’s transition into systematic human data generation across its Australian clinical network.</p> <p align="justify">NPX-5 is http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html Thu, 23 Apr 2026 07:00:00 -0400 A.06822034 A.17150087 O.20026344 O.49223070 O.65258044 PBM http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html <p align="justify">NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.</p> <p align="justify">The initiation of dosing represents the first active clinical evaluation of NPX-5 at scale and marks the Company’s transition into systematic human data generation across its Australian clinical network.</p> <p align="justify">NPX-5 is http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html Thu, 23 Apr 2026 07:00:00 -0400 A.06822034 A.17150087 O.20026344 O.49223070 O.65258044 PBM http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html <p align="justify">NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.</p> <p align="justify">The initiation of dosing represents the first active clinical evaluation of NPX-5 at scale and marks the Company’s transition into systematic human data generation across its Australian clinical network.</p> <p align="justify">NPX-5 is http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html Thu, 23 Apr 2026 07:00:00 -0400 A.06822034 A.17150087 O.20026344 O.49223070 O.65258044 PBM http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html <p align="justify">NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.</p> <p align="justify">The initiation of dosing represents the first active clinical evaluation of NPX-5 at scale and marks the Company’s transition into systematic human data generation across its Australian clinical network.</p> <p align="justify">NPX-5 is http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html Thu, 23 Apr 2026 07:00:00 -0400 A.06822034 A.17150087 O.20026344 O.49223070 O.65258044 PBM http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html <p align="justify">NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.</p> <p align="justify">The initiation of dosing represents the first active clinical evaluation of NPX-5 at scale and marks the Company’s transition into systematic human data generation across its Australian clinical network.</p> <p align="justify">NPX-5 is http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Initiates+Patient+Dosing+in+Phase+IIb+Trial+Evaluating+NPX-5+for+Adjustment+Disorder/26354337.html Thu, 23 Apr 2026 07:00:00 -0400 A.06822034 A.17150087 O.20026344 O.49223070 O.65258044 PBM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Apr+17/26341313.html si-local-file:///var/storage/secattach/20260421/26341313.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Apr+17/26341313.html Tue, 21 Apr 2026 09:07:00 -0400 O.65258044 PBM